MedTrace Logo

Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer

NCT01020864 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-11-02

No results posted yet for this study

Summary

This is an open, multicenter phase II study. The purpose is to demonstrate the efficacy of cetuximab in combination with carboplatin and vinorelbine as second line treatment in patients with recurrent or metastatic head and neck cancer who have progressed during or after treatment with first line cisplatinum.

Conditions

  • Head and Neck Neoplasms

Interventions

DRUG

Cetuximab

Cetuximab 500 mg/m² i.v. day 1, every 2nd week

DRUG

Carboplatin

Carboplatin AUC = 3 i.v. day 1, every 21nd week

DRUG

Vinorelbine

Vinorelbine 25 mg/m² i.v. day 1, every 2nd week

Sponsors & Collaborators

  • Odense University Hospital

    collaborator OTHER

  • Per Pfeiffer

    lead OTHER

Principal Investigators

  • Per Pfeiffer, Professor, MD, PhD · Odense University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01020864 on ClinicalTrials.gov